Bio-Rad Laboratories Class A
406 hedge funds and large institutions have $6.62B invested in Bio-Rad Laboratories Class A in 2020 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 143 increasing their positions, 138 reducing their positions, and 42 closing their positions.
83% more funds holding in top 10
Funds holding in top 10: 6 → 11 (+5)
55% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 42
5% more funds holding
Funds holding: 387 → 406 (+19)
4% more repeat investments, than reductions
Existing positions increased: 143 | Existing positions reduced: 138
0.73% less ownership
Funds ownership: 76.77% → 76.04% (-0.73%)
6% less capital invested
Capital invested by funds: $7.02B → $6.62B (-$397M)
49% less call options, than puts
Call options by funds: $6.51M | Put options by funds: $12.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Pelham Capital
London,
United Kingdom
|
+$67.7M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$55.7M |
| 3 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
+$53.7M |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
+$42.6M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Atlanta Capital Management
Atlanta,
Georgia
|
-$108M |
| 2 |
Millennium Management
New York
|
-$54.2M |
| 3 |
Two Sigma Investments
New York
|
-$32.4M |
| 4 |
BlackRock
New York
|
-$30.8M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$28.5M |
BIO Hedge Fund Activity: Q1 2020 in Review
406 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q1 2020, worth a combined $6.62B — down 5.7% from $7.02B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new BIO positions and 42 closed out — a net gain of 23 holders — while 143 added to existing stakes and 138 trimmed.
The largest buyer was Pelham Capital, opening a new position worth an estimated $67.7M. The largest seller was Atlanta Capital Management, cutting an estimated $108M.
- 406 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q1 2020, up from 387 in Q4 2019.
- Funds reported $6.62B of Bio-Rad Laboratories Class A stock for Q1 2020, down 5.7% quarter-over-quarter.
- 65 funds opened new Bio-Rad Laboratories Class A positions in Q1 2020 and 42 closed out, a net change of +23 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q1 2020 was Pelham Capital, an estimated $67.7M added.
- The largest Bio-Rad Laboratories Class A seller in Q1 2020 was Atlanta Capital Management, an estimated $108M sold.
Based on aggregated 13F filings for Q1 2020.